NCT06923280View on ClinicalTrials.gov

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

May 31, 2028

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Pegylated Interferon-alpha (IFN)

pegylated interferon-alpha 180 μg once weekly for 24 weeks

Trial Locations (1)

Unknown

Huashan Hospita, Shanghai

All Listed Sponsors
lead

Huashan Hospital

OTHER

NCT06923280 - Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens | Biotech Hunter | Biotech Hunter